The atypical PKC scaffold protein P62 is a novel target for anti-inflammatory and anti-cancer therapies.
Centro de Biología Molecular Severo Ochoa, Universidad Autónoma, Canto Blanco, 28049 Madrid, Spain.
Jorge
J
Moscat
María T
MT
Diaz-Meco
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002352:Carrier Proteins / Q000737:chemistry*; D006801:Humans; D050356:Lipid Metabolism; D048671:MAP Kinase Kinase 5; D020929:Mitogen-Activated Protein Kinase Kinases / Q000378:metabolism; D008954:Models, Biological; D016328:NF-kappa B / Q000378:metabolism; D020932:Nerve Growth Factor / Q000378:metabolism; D011485:Protein Binding; D020033:Protein Isoforms; D011493:Protein Kinase C / Q000378:metabolism*; D017434:Protein Structure, Tertiary; D015398:Signal Transduction; D014407:Tumor Cells, Cultured; D015032:Zinc / Q000378:metabolism
D000970:Antineoplastic Agents; D002352:Carrier Proteins; D016328:NF-kappa B; D020033:Protein Isoforms; D020932:Nerve Growth Factor; D011493:Protein Kinase C; D048671:MAP Kinase Kinase 5; C482563:MAP2K5 protein, human; D020929:Mitogen-Activated Protein Kinase Kinases; D015032:Zinc